Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

271 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial.
Bernsdorf M, Ingvar C, Jörgensen L, Tuxen MK, Jakobsen EH, Saetersdal A, Kimper-Karl ML, Kroman N, Balslev E, Ejlertsen B. Bernsdorf M, et al. Among authors: ejlertsen b. Breast Cancer Res Treat. 2011 Apr;126(2):463-70. doi: 10.1007/s10549-011-1352-2. Epub 2011 Jan 15. Breast Cancer Res Treat. 2011. PMID: 21234672 Clinical Trial.
retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, Schonau A, Gunnarsdóttir K, Olsen KE, Mouridsen H, Ejlertsen B; Danish Breast Cancer Cooperative Group. Knoop AS, et al. Among authors: ejlertsen b. J Clin Oncol. 2005 Oct 20;23(30):7483-90. doi: 10.1200/JCO.2005.11.007. J Clin Oncol. 2005. PMID: 16234514 Clinical Trial.
Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer.
Ejlertsen B, Mouridsen HT, Jensen MB, Bengtsson NO, Bergh J, Cold S, Edlund P, Ewertz M, de Graaf PW, Kamby C, Nielsen DL. Ejlertsen B, et al. J Clin Oncol. 2006 Nov 1;24(31):4956-62. doi: 10.1200/JCO.2005.05.1235. J Clin Oncol. 2006. PMID: 17075113 Clinical Trial.
Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study.
Bertelsen L, Bernstein L, Olsen JH, Mellemkjaer L, Haile RW, Lynch CF, Malone KE, Anton-Culver H, Christensen J, Langholz B, Thomas DC, Begg CB, Capanu M, Ejlertsen B, Stovall M, Boice JD Jr, Shore RE; Women's Environment, Cancer and Radiation Epidemiology Study Collaborative Group; Bernstein JL. Bertelsen L, et al. Among authors: ejlertsen b. J Natl Cancer Inst. 2008 Jan 2;100(1):32-40. doi: 10.1093/jnci/djm267. Epub 2007 Dec 25. J Natl Cancer Inst. 2008. PMID: 18159070
271 results